Please login to the form below

Lixiana

This page shows the latest Lixiana news and features for those working in and with pharma, biotech and healthcare.

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

Daiichi Sankyo to shut down German antibody unit U3

Daiichi Sankyo is looking to new products such as novel oral anticoagulant (NOAC) Lixiana (edoxaban) - as well as pipeline candidates like tivantinib for liver cancer, quizartinib for leukaemia and mirogabalin for
Daiichi Sankyo cuts a swathe through US workforce

The company is hoping that newer products such as novel oral anticoagulant (NOAC) Savaysa/Lixiana (edoxaban) will eventually fill the void left by Benicar, which is facing a challenging start as
Daiichi Sankyo licenses clot-busting antibody

The Japanese drugmaker is already a major player in the thrombosis market with products such as Eli Lilly-partnered antiplatelet drug Effient (prasugrel) and recently-introduced NOAC Lixiana (edoxaban).
NICE recommends Daiichi Sankyo's Lixiana for DVT and PE

NICE recommends Daiichi Sankyo's Lixiana for DVT and PE. Institute's final guidance concludes the novel oral anticoagulant is cost effective. ... In terms of its clinical effectiveness Daiichi said Lixiana proven efficacy and a significantly better
Daiichi’s new anticoagulant recommended by NICE

Daiichi’ s new anticoagulant recommended by NICE. Lixiana nears NHS funding approval for certain patients with atrial fibrillation. ... NICE has already recommended Lixiana for the treatment of deep vein thrombosis and pulmonary embolism, and

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Modern anticoagulants threaten status quo

trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Add my company

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...